* New clinical studies (223) include clinical trials, post authorization studies and medical device studies.
New
175
New clinical trials
40
EOM (Post authorization study)
8
MD (Medical device study)
Active
672
Clinical trials
255
EOM (Post authorization study)
48
MD (Medical device study)
196
Clinical Trials on Rare Diseases
204
Clinial Trials on Pediatrics
773
Clinical Trials patient inclusions in 2022
Active Clinical Studies 5-year evolution
Patient inclusions 5-year evolution
Active Clinical Studies by eCORE
11.23%
Global Health
22.70%
Chronic, Prevalent Diseases
& Aging
14.97%
Woman & Child Health &
Rare Diseases
7.77%
Brain & Mind and Behaviour
4.68%
Cancer
13.99%
Personalised Medicine, Innovative Diagnostics, Molecular Imaging & Digital Health
20.96%
Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation
3.70%
Others
Billing evolution of clinical studies
| 2018 | 2019 | 2020 | 2021 | 2022 | |
| Phase I-II | 1.55M€ | 2.36M€ | 2.42M€ | 3.26M€ | 3.29M€ |
| Phase III | 3.52M€ | 3.19M€ | 3.36M€ | 4.34M€ | 4.39M€ |
| Phase IV | 0.14M€ | 0.11M€ | 0.14M€ | 0.29M€ | 0.29M€ |
| EOM/MD | 0.42M€ | 0.78M€ | 0.35M€ | 0.35M€ | 0.35M€ |
| TOTAL | 5.63M€ | 0.64M€ | 6.28M€ | 8.24M€ | 8.33M€ |
Methodology and Definitions
The data are at VHIR level, not at Campus level (not including data from VHIO/Adult Oncology and Hematology Services).
The data includes commercial and academic studies that are registered in the database.
eCORE “Others”: studies of researchers who are not part of any research area of VHIR but belong to a Service of Vall d’Hebron Hospital.
New: studies with signed contract+AEMPS+CEIm.
Active: active+new+closed studies in the year.
